Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Molecular Virology Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India.
Front Immunol. 2018 Mar 27;9:618. doi: 10.3389/fimmu.2018.00618. eCollection 2018.
Strain-specific neutralizing antibodies develop in all human immunodeficiency virus type 1 (HIV-1)-infected individuals. However, only 10-30% of infected individuals produce broadly neutralizing antibodies (bNAbs). Identification and characterization of these bNAbs and understanding their evolution dynamics are critical for obtaining useful clues for the development of an effective HIV vaccine. Very recently, we published a study in which we identified 12 HIV-1 subtype C-infected individuals from India whose plasma showed potent and broad cross-clade neutralization (BCN) ability (1). In the present study, we report our findings on the evolution of host bNAb response over a period of 4 years in a subset of these individuals. Three of the five individuals (NAB033, NAB059, and NAB065) demonstrated a significant increase ( < 0.05) in potency. Interestingly, two of the three samples also showed a significant increase in CD4 binding site-specific antibody response, maintained stable CD4+ T cell counts (>350 cells/mm) and continued to remain ART-naïve for more than 10 years after initial diagnosis, implying a strong clinical correlation with the development and evolution of broadly neutralizing antibody response against HIV-1.
所有人类免疫缺陷病毒 1 型（HIV-1）感染者体内均会产生针对特定毒株的中和抗体。然而，仅有 10%-30%的感染者能产生广谱中和抗体（bnAbs）。对这些 bnAbs 的鉴定和特性分析及其进化动态的研究，对于寻找有效的 HIV 疫苗开发线索至关重要。最近，我们发表了一项研究，鉴定了来自印度的 12 名 HIV-1 亚型 C 感染者，他们的血浆显示出强大的广谱跨群中和（BCN）能力（1）。在本研究中，我们报告了对其中部分个体 4 年内宿主 bnAb 反应进化的研究结果。在这 5 名个体中的 3 名（NAB033、NAB059 和 NAB065）显示出中和效力显著增加（ < 0.05）。有趣的是，其中两个样本的 CD4 结合位点特异性抗体反应也显著增加，CD4+T 细胞计数保持稳定（>350 个细胞/mm），且在初始诊断后 10 多年内仍持续未接受抗逆转录病毒治疗（ART），这表明与 HIV-1 广谱中和抗体反应的产生和进化具有很强的临床相关性。
